Pathogenic Mitochondria DNA Mutations: Current Detection Tools and Interventions

被引:39
作者
Mustafa, Mohd Fazirul [1 ]
Fakurazi, Sharida [1 ]
Abdullah, Maizaton Atmadini [2 ,3 ]
Maniam, Sandra [1 ]
机构
[1] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Selangor Darul Ehsan 43400, Malaysia
[2] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Pathol, Selangor Darul Ehsan 43400, Malaysia
[3] Univ Putra Malaysia, Inst Biosci, Mol Med Lab, Selangor Darul Ehsan 43400, Malaysia
关键词
mitochondrial DNA; mitochondria DNA mutations; mitochondrial DNA diseases; mitochondria transfer; genetic intervention; HEREDITARY OPTIC NEUROPATHY; RAGGED-RED FIBERS; STROKE-LIKE-EPISODES; LACTIC-ACIDOSIS; OXIDATIVE-PHOSPHORYLATION; SELECTIVE DEGRADATION; MYOCLONIC EPILEPSY; LEIGH-SYNDROME; COMPLEX-I; ND5; GENE;
D O I
10.3390/genes11020192
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Mitochondria are best known for their role in energy production, and they are the only mammalian organelles that contain their own genomes. The mitochondrial genome mutation rate is reported to be 10-17 times higher compared to nuclear genomes as a result of oxidative damage caused by reactive oxygen species during oxidative phosphorylation. Pathogenic mitochondrial DNA mutations result in mitochondrial DNA disorders, which are among the most common inherited human diseases. Interventions of mitochondrial DNA disorders involve either the transfer of viable isolated mitochondria to recipient cells or genetically modifying the mitochondrial genome to improve therapeutic outcome. This review outlines the common mitochondrial DNA disorders and the key advances in the past decade necessary to improve the current knowledge on mitochondrial disease intervention. Although it is now 31 years since the first description of patients with pathogenic mitochondrial DNA was reported, the treatment for mitochondrial disease is often inadequate and mostly palliative. Advancements in diagnostic technology improved the molecular diagnosis of previously unresolved cases, and they provide new insight into the pathogenesis and genetic changes in mitochondrial DNA diseases.
引用
收藏
页数:13
相关论文
共 81 条
[11]  
2-P
[12]  
Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8
[13]   Finding an ethical path forward for mitochondrial replacement [J].
Claiborne, Anne B. ;
English, Rebecca A. ;
Kahn, Jeffrey P. .
SCIENCE, 2016, 351 (6274) :668-670
[14]  
Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO
[15]  
2-T
[16]   Recent Advances in Mitochondrial Disease [J].
Craven, Lyndsey ;
Alston, Charlotte L. ;
Taylor, Robert W. ;
Turnbull, Doug M. .
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 18, 2017, 18 :257-275
[17]   Novel reproductive technologies to prevent mitochondrial disease [J].
Craven, Lyndsey ;
Tang, Mao-Xing ;
Gorman, Grainne S. ;
De Sutter, Petra ;
Heindryckx, Bjorn .
HUMAN REPRODUCTION UPDATE, 2017, 23 (05) :501-519
[18]   Gene therapy for mitochondrial diseases: Leber Hereditary Optic Neuropathy as the first candidate for a clinical trial [J].
Cwerman-Thibault, Helene ;
Augustin, Sebastien ;
Ellouze, Sami ;
Sahel, Jose-Alain ;
Corral-Debrinski, Marisol .
COMPTES RENDUS BIOLOGIES, 2014, 337 (03) :193-206
[19]   A slippery slope to human germline modification [J].
Darnovsky, Marcy .
NATURE, 2013, 499 (7457) :127-127
[20]   Mitochondrial-nuclear DNA mismatch matters [J].
Dunham-Snary, Kimberly J. ;
Ballinger, Scott W. .
SCIENCE, 2015, 349 (6255) :1449-1450